We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

GLP-1 · 6 min read

GLP-1 medications and menopause: a clinical perspective

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

GLP-1 medications can be a powerful tool in midlife weight management — when used thoughtfully.

GLP-1 receptor agonists — semaglutide and tirzepatide most commonly — produce meaningful weight loss in patients who meet criteria. In menopause, where metabolism shifts and visceral fat accumulates, they can be especially useful.

How we use them

  • Always paired with resistance training to protect muscle mass
  • Adequate protein — 1.2–1.6 g/kg body weight per day
  • Coordinated with HRT when indicated
  • Slow, careful dose titration to manage GI side effects

Risks to know

FDA-approved GLP-1 receptor agonists (and dual GIP/GLP-1 agonists such as tirzepatide) have important risks. Most, including semaglutide, liraglutide, dulaglutide and tirzepatide, carry a boxed warning about thyroid C-cell tumors seen in rodents; it is not known whether they cause these tumors, including medullary thyroid cancer, in people. They should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other serious risks can include pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems often linked to dehydration, and serious allergic reactions. On November 9, 2026, FDA required safety labeling changes for GLP-1 RAs for a potential increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION)—sudden, painless vision loss in one eye that can include permanent vision loss. Contact a clinician right away if your vision changes suddenly. Common side effects include nausea, vomiting, diarrhea, and constipation. Naming a medicine does not mean Kindr Health prescribes it. Talk with a licensed clinician and read the full prescribing information.

GLP-1 medications are tools, not magic. The patients who do best are the ones who change behavior alongside the medication.

Sources

Menopause weight gain has a cause — and a protocol.

The metabolic slowdown of menopause is driven by estrogen-related insulin resistance, cortisol, and muscle loss. The kindr Metabolic Reset addresses all three.

See the Metabolic Reset →On a GLP-1? Start here →
Prescription weight care → talk to a physician

Medically reviewed by Kindr Health Clinical Team
Last updated: May 10, 2026

More on weight & metabolic health

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Who shouldn't take hormone therapy? Contraindications, gray areas, and your non-hormonal options.

A recent conference presentation found that hormone therapy prescribing despite a documented contraindication is rising in primary care. Here's what current FDA labels list as contraindications, where an individualized discussion comes in, and which nonhormonal options a major guideline suggests.

Research

Is there an age limit on hormone therapy? Timing, the 10-year window, and HT after 60 and 65.

A SWAN analysis and current FDA and ACOG guidance frame hormone therapy around timing and individual history, not a single age cutoff. Here's what that means for starting, continuing after 60 or 65, and what to ask a clinician.

Research

Strong through menopause: why muscle matters, especially if you're on a GLP-1

A trial of 120 midlife adults on tirzepatide found that lifting three times a week reduced lean-tissue loss and raised strength, with similar weight loss. Here's what that means if you're navigating menopause, and what to discuss with your clinician before you start.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →